MYC and cancer: Junttila et al. [37] first described that CIP2A associates with and stabilises MYC in Hela cells, increasing MYC’s half-life and its activation (indicated by phosphorylation on serine 62) as well as promoting MYC localisation to nuclear lamins in cancer cell lines [37,38,39,40].